We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
-5.73%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.16B
AUM Growth
+$104M
Cap. Flow
-$1.09B
Cap. Flow %
-34.59%
Top 10 Hldgs %
35.35%
Holding
97
New
14
Increased
28
Reduced
11
Closed
11

Top Buys

Rank Stock Value
1
BCYC
Bicycle Therapeutics
BCYC
+$29.5M
2
ETNB
89bio
ETNB
+$26.7M
3
IMCR icon
Immunocore
IMCR
+$26M
4
TMO icon
Thermo Fisher Scientific
TMO
+$25.8M
5
INSP icon
Inspire Medical Systems
INSP
+$25.3M

Top Sells

Rank Stock Value
1
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$47.8M
2
BIIB icon
Biogen
BIIB
+$34.7M
3
ALGN icon
Align Technology
ALGN
+$34.1M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$30.1M
5
GKOS icon
Glaukos
GKOS
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 51.8%
2 Miscellaneous 47.89%
3 Consumer Staples 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$15.7B
$109M 3.44%
968,024
+34,662
+4% +$3.65M
PCVX icon
2
Vaxcyte
PCVX
$8.9B
$82.6M 2.61%
1,619,553
-102,800
-6% -$5.07M
XENE icon
3
Xenon Pharmaceuticals
XENE
$5.81B
$71.9M 2.27%
2,103,396
+275,043
+15% +$10.3M
BSX icon
4
Boston Scientific
BSX
$67.9B
$61.5M 1.94%
1,164,850
+447,800
+62% +$23.5M
LEGN icon
5
Legend Biotech
LEGN
$3.87B
$59.1M 1.87%
879,564
+323,263
+58% +$22.5M
IRTC icon
6
iRhythm Holdings
IRTC
$3.96B
$53.6M 1.69%
568,157
+89,600
+19% +$9.11M
GKOS icon
7
Glaukos
GKOS
$10.6B
$52.4M 1.65%
695,792
-348,600
-33% -$26M
IMCR icon
8
Immunocore
IMCR
$1.89B
$47.1M 1.49%
906,973
+438,946
+94% +$26M
DAWN
9
DELISTED
Day One Biopharmaceuticals
DAWN
$45.6M 1.44%
3,715,573
+353,760
+11% +$4.61M
NTRA icon
10
Natera
NTRA
$47B
$44.8M 1.42%
1,012,145
-140,706
-12% -$7.18M
KROS icon
11
Keros Therapeutics
KROS
$219M
$43.3M 1.37%
1,357,309
+213,444
+19% +$7.97M
DCPH
12
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$42.4M 1.34%
3,336,221
-310,198
-9% -$4.28M
FNA
13
DELISTED
Paragon 28, Inc.
FNA
$42.2M 1.33%
3,361,824
+1,225,702
+57% +$18.5M
MRVI icon
14
Maravai LifeSciences
MRVI
$1.14B
$39.7M 1.26%
3,974,857
+2,170,157
+120% +$23.8M
TMO icon
15
Thermo Fisher Scientific
TMO
$230B
$38.3M 1.21%
75,749
+48,449
+177% +$25.8M
ALGN icon
16
Align Technology
ALGN
$11.2B
$38.2M 1.21%
125,213
-98,817
-44% -$34.1M
BCRX icon
17
BioCryst Pharmaceuticals
BCRX
$2.51B
$38M 1.2%
5,362,980
+2,571,100
+92% +$18.5M
NVRO
18
DELISTED
NEVRO CORP.
NVRO
$34.1M 1.08%
1,776,368
– –
KIDS icon
19
OrthoPediatrics
KIDS
$617M
$33.8M 1.07%
1,057,770
+296,562
+39% +$11.4M
ISRG icon
20
Intuitive Surgical
ISRG
$132B
$33.6M 1.06%
114,920
-8,900
-7% -$2.78M
VRDN icon
21
Viridian Therapeutics
VRDN
$2.61B
$26.6M 0.84%
1,735,182
+528,882
+44% +$10.1M
ALEC icon
22
Alector
ALEC
$261M
$26.4M 0.83%
4,074,120
-57,195
-1% -$370K
OM icon
23
Outset Medical
OM
$74.1M
$26.1M 0.83%
160,028
+62,670
+64% +$14.8M
HROW icon
24
Harrow
HROW
$1.4B
$26M 0.82%
1,808,684
+356,146
+25% +$6.23M
BCYC
25
Bicycle Therapeutics
BCYC
$294M
$25.9M 0.82%
+1,289,872
New +$29.5M
1
2 3

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q3 2023 Portfolio in Review

As of Q3 2023, Braidwell held 97 positions worth $3.16B, up 3.4% from $3.06B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Braidwell withdrew a net $1.09B in Q3 2023, closing 11 positions and reducing 11 holdings. Its most notable exit was DICE Therapeutics, Inc. Common Stock, an estimated $47.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 54% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Braidwell opened a new position in Bicycle Therapeutics worth $25.9M.

  • Braidwell's largest Q3 2023 buy was Bicycle Therapeutics: 1,289,872 shares worth $25.9M.
  • Braidwell added most to Immunocore in Q3 2023, an estimated $26M increase.
  • Braidwell's biggest Q3 2023 reduction was Align Technology, cutting an estimated $34.1M.
  • Braidwell fully exited DICE Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $47.8M.
  • Braidwell's ten largest holdings make up 35% of its $3.16B portfolio in Q3 2023.
  • Braidwell opened 14 new positions and closed 11 in Q3 2023.
  • Braidwell's portfolio value rose 3.4% quarter-over-quarter to $3.16B.

Based on Braidwell's 13F filing for Q3 2023, filed 14 Nov 2023.